LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
FAIL · Does not pass the screen
39.34 USD
Price as of 26 Oct 2026Daily close, not a live quote
Screened 2026-10-26 · the tape above runs as of 16:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price39.34 USD at the 26 Oct 2026 close
Ethical screenDoes not pass
Last reviewed26 Oct 2026 (3 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 39.34 against the desk's fair-value range, base estimate 55.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price39.34 USD
Fair value55.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-25Read Distribution34.79+13.1% to today Markdown gives way to Distribution after a 19% slide in 3 weeks
2026-10-02Read Markdown42.69-7.8% to today ✓Accumulation gives way to Markdown after a 50% rise in 4 weeks
2026-09-04Read Accumulation28.42+38.4% to today ✓Markup gives way to Accumulation
2026-08-04Read Markup28.42+38.4% to today ✓Markdown gives way to Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
LB Pharmaceuticals Inc holds its Accumulation at $39.34. The statistical read favours the sellers, held for 27 days.
As held on the ledger · 2026-10-26
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 27 days
Price at the screen
$39.34
Valuation
393.40 trailing · -7.67 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.14%
Below 33%
Interest-bearing debt is just 1.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
14.39%
Below 33%
Cash held in interest-bearing accounts and securities is 14.4% of assets, under the one-third limit.
Pass
Receivables
79.94%
Below 49%
Money owed to the company is 79.9% of assets, above the 49% limit.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
LB Pharmaceuticals's business is fine, but its receivables are about 80% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when LBRX's ethical verdict changes
Today LBRX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-26 screen. The gold marker is the market price at the same screen. A 39.8% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +40% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LBRX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (6 analysts) rates it strong buy, with a mean price target of $45.
2026-10-18Markdown$34.79-18.5%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 18.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (6 analysts) rates it strong buy, with a mean price target of $45.
2026-10-02Markdown · changed$42.69+50.2%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 50.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (6 analysts) rates it strong buy, with a mean price target of $45. Since the last review it its composite score eased.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (6 analysts) rates it strong buy, with a mean price target of $45.
2026-08-04Markup · changed$28.42+0.0%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (6 analysts) rates it strong buy, with a mean price target of $45.
2026-07-18Markdown$28.42+0.0%Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (6 analysts) rates it strong buy, with a mean price target of $45.
2026-07-03Markdown$28.42+0.0%Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$28.42Entry 1
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.